



Drug Development - Roadmap to U.S. FDA Clinical Trial

Date: **23 January 2025 (Thursday)**

Time: **2:30 – 6:00 pm** (registration starts at 2:00 pm)

- 2:30 – 4:00 pm *Symposium*
- 4:00 – 6:00 pm *Networking*

Venue: **Grand Hall A, Phase 3, Hong Kong Science Park, Shatin, New Territories**

Tentative Programme*

2:30 pm	<p>Welcome Remarks</p> <p>Prof. Alexander Ping-kong Wai, JP, President and Vice-Chancellor, Hong Kong Baptist University (HKBU)</p>
2:35 pm	<p>Ceremonial Speech by Guest of Honour</p> <p>Ms. Lillian Man Lei Cheong, JP, Under Secretary for Innovation, Technology and Industry, Innovation, Technology and Industry Bureau, The Government of the HKSAR</p>
2:40 pm	<p>Introduction of Pharmaceutical Sciences and Medical Innovation at HKBU</p> <p>Dr. Ken Yeung, Director of Technology Translation, the Institute for Innovation, Translation and Policy Research, Hong Kong Baptist University</p>
2:50 pm	<p>About Hong Kong Science and Technology Parks Corporation</p> <p>Dr. Grace Lau, Head, Life and Health Technology, Hong Kong Science and Technology Parks Corporation</p>
3:05 pm	<p>Collaboration Announcement between Hong Kong Baptist University, Macau University of Science and Technology and Avalon BioMedical Management Limited</p>



3:10 pm **Keynotes Speeches**

- Prof. Hon Dennis Lam, JP, Hong Kong Deputy to the National People's Congress; Member of Legislative Council, The Government of HKSAR; Adjunct Senior Investigator, Hong Kong Baptist University
- Prof. Johnson Yiu-nam Lau, Adjunct Senior Investigator, Hong Kong Baptist University
- Prof. Bian Zhaoxiang, MH, Associate Vice-President (Clinical Chinese Medicine), Hong Kong Baptist University

3:40 pm **Project Showcase: Life Sciences & Drug Development at HKBU**

- Prof. Zhang Ge, Associate Dean (Research) of Chinese Medicine; Director, Technology Development Division & Professor, Teaching and Research Division, School of Chinese Medicine, Hong Kong Baptist University
- Prof. Cheung Yiu Ming, RGC Senior Research Fellow, Chair Professor, Department of Computer Science, Hong Kong Baptist University – Ms. Mengyao Chen, Sales & Marketing Officer, IntelligenceX Limited
- Dr. Liu Edward Shiu Fai, Adjunct Investigator, Hong Kong Baptist University
- Dr. Aik Wei Shen, Assistant Professor, Department of Chemistry, Hong Kong Baptist University

4:00 pm – **Networking Cocktail**

6:00 pm

**Note: Programme and schedule are subject to change.*

Biographies of Keynote Speakers



Professor Hon Dennis LAM, JP

Hong Kong Deputy to the National People's Congress; Member of Legislative Council, The Government of HKSAR; Adjunct Senior Investigator, The Institute for Innovation, Translation and Policy Research, Hong Kong Baptist University

- Honoree of the Power List- "Top 100 Ophthalmologists in the World" for seven consecutive years (2024: ranked #1 in Asia and #6 in the world)
- >800 SCI publication; H-index 85
- "World Top 0.05% Scholar" by ScholarGPS in 2024
- Founder and Chairman of C-MER Medical Holdings Limited (stock code: 3309.hk)
- Founder and Chairman of Health Hope Pharma

Prof. Lam is an accomplished clinician-scientist and a well-known figure in the field of ophthalmology in the Asia-Pacific region (APAC) and worldwide. He has established C-MER Medical Holdings Limited for providing medical services and Health Hope Pharma for new drugs and devices development.

Prof. Lam was elected "World Top 0.05% Scholar" by the ScholarGPS in 2024 and ranked #1 in the "Lifetime Highly Ranked Scholar" in the field of Ophthalmology in China. The Asia-Pacific Academy of Ophthalmology (APAO) and the Asia-Pacific Vitreo-Retina Society (APVRS) have established the "APAO Dennis Lam Lecture" and "APVRS Dennis Lam Lecture" in 2023 and 2025 respectively.

He was the President & Organizing Committee Chairman of the World Ophthalmology Congress (WOC) 2008, the Associate Dean (External Affairs) of the Faculty of Medicine, The Chinese University of Hong Kong (CUHK) (2004-2009), the Chairman of the Department of Ophthalmology & Visual Sciences (DOVS), CUHK (1998-2011), the Director of State Key Lab (Ophthalmology) of the Zhongshan Ophthalmic Center of the Zhongshan University of China (2012-2016), and currently the Director of the Primasia International Eye Research Institute (PIERI) of the Chinese University of Hong Kong (Shenzhen), China (2017-present). He is currently serving as President of the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII), Secretary-General of the Asia-Pacific Myopia Society (APMS), and Asia-Pacific Artificial Cornea Society (APACS), a Council Member of the World Glaucoma Association (WGA) and an Academician of the Academia Ophthalmologica Internationalis (AOI). Lastly, he is former President of APAO and APVRS, and Founding President of Asia-Pacific Society of Eye Genetic (APSEG). Dr. Lam established the Asia-Pacific Journal of Ophthalmology (APJO) in 2012 and has served as the editor-in-chief since then; the APJO ranked #1 in Asia, #1 in APAC, and #7 in the world in 2023. He has also served in editorial boards of over 10 international eye journals.

Biographies of Keynote Speakers



Professor Johnson Yiu-nam LAU

Adjunct Senior Investigator, The Institute for Innovation, Translation and Policy Research, Hong Kong Baptist University

- Former senior executive at Schering-Plough/Merck
- Led 5 novel blockbuster drugs (NDA/BLA)
- Launched the second largest biotech IPO in U.S. history in 2002 as CEO (NYSE)
- Chairman/CEO of another biotech (Nasdaq, Russell 2000 index)
- H-index 83

Prof. Lau has extensive pharmaceutical executive/leadership experience in both scientific and business management. He was the Chairman of the Board of Athenex since its inception, also assumed the CEO role in 2011, and launched its IPO in 2017 in Nasdaq (and listed in Russell 2000 index). Prior, as CEO, he launched the second-largest biotech IPO in US history in 2002 (Ribapharm, NYSE). Prior, he served as Head of Worldwide Research and Development for ICN Pharmaceuticals (NYSE). Prior, he was Senior Director of Antiviral Therapy at Schering-Plough (now Merck), and led programs that developed oral ribavirin, pegylated interferon-alfa2b, and Boceprevir. He previously held directorial roles at several notable companies, including Chelsea Therapeutics (Nasdaq), Celsius Therapeutics (AIM), c-Mer Eyecare Holdings (HKSE), Porton Fine Chemicals (Shenzhen Exchange), XenoBiotic Laboratories (acquired by WuXi AppTec), Aiviva, and the board of the charity Project Vision. He currently serves on the boards of Avalon Biomedical (Management) Limited, D& J Pharma, and the Hong Kong X-tech Startup platform.

In 2010, Prof. Lau was honored as an Asian American Visionary in the field of Pharmaceutical and Biotechnology by the Asia Society, Southern California Chapter, and received recognition from the U.S. Congress, California Legislative Assembly, and the City of Los Angeles.

Prof. Lau graduated from the Medical Faculty of the University of Hong Kong in 1984 and received training in Internal Medicine, Gastroenterology, and Hepatology. He received his MRCP in 1987 and a Croucher Foundation Fellowship to study Viral Hepatitis and Liver Transplantation at King's College London, where he later joined the faculty. He also obtained his MD in 1992. He later joined the University of Florida faculty, where he helped establish a top Liver Transplantation program and received NIH (R01) support for his research on Hepatitis C.

Biographies of Keynote Speakers



Professor BIAN Zhaoxiang, MH

Associate Vice-President (Clinical Chinese Medicine), Hong Kong Baptist University

- Director, Centre for Chinese Herbal Medicine Drug Development Limited
- Leading Herbal Medicine Development of CDD-2101 (U.S. FDA IND approval), CDD-2103 (China NMPA IND approval), CDD-2107 (U.S. FDA Orphan Drug Designation)

Prof. Bian Zhaoxiang is a leading expert in Chinese medicine clinical studies, a respected research scientist in the field of gut dysbiosis, and a relentless advocate for incorporating Chinese medicine into a holistic healthcare system. Prof. Bian currently holds several key positions at the School of Chinese Medicine at HKBU, including Associate Vice-President (Clinical Chinese Medicine), Chair Professor in Chinese Medicine, and Director of the Centre for Chinese Herbal Medicine Drug Development, the Chinese EQUATOR Centre, the Hong Kong Chinese Medicine Clinical Study Centre and the Vincent V.C. Woo Chinese Medicine Clinical Research Institute. He serves as an associate editor and editorial board member for various international peer-reviewed journals, such as *Trials* and *BMC-Complementary and Alternative Medicine*.

His research focuses on digestive diseases, particularly colorectal cancer, irritable bowel syndrome (IBS), functional constipation (FC), and inflammatory bowel disease (IBD), along with new drug discovery. Prof. Bian is also dedicated to the design and reporting of clinical trials involving Chinese medicine. He established the Hong Kong Chinese Medicine Clinical Study Centre, the first center in Hong Kong dedicated to clinical trials in Chinese medicine and has developed reporting guidelines for various aspects of this field.

A long-time advocate for a Chinese medicine hospital (CMH) in Hong Kong, Prof. Bian's efforts led to HKBU being selected by the HKSAR Government as the operator for the first CMH. As of August 2021, he has registered 72 patents and published over 500 papers. Notably, he led a research team that developed a new herbal medicine for IBS, receiving a clinical trial license in 2014. Prof. Bian has received numerous awards for his research, including the second prize in the National Science and Technology Advancement Award of China.

Biographies of Speakers



Professor ZHANG Ge

Associate Dean (Research) of Chinese Medicine,
Hong Kong Baptist University

- Director, Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases
- Director of the Institute of Precision Medicine and Innovative Drug Research

In 2012, Prof. Zhang Ge joined Hong Kong Baptist University. His research focus is in basic science & clinical translational research in orthopedics & traumatology, including osteoporosis, osteonecrosis, fracture repair osteoarthritis and rheumatoid arthritis. Prof. Zhang has led his group to publish a series of research works in Nature Medicine, Arthritis & Rheumatism, Journal of Bone & Mineral Research, Bone and Osteoporosis International.

He also serves as the Executive Director of the Guangdong-Hong Kong-Macao Greater Bay Area Aptamer Translational Medicine and Drug Discovery International Cooperation Platform and is the President of the Hong Kong Pharmaceutical Society.

Prof. Zhang is recognized among the top 2% of scientists globally, as published by Stanford University, and ranks among the top 10 scientists in terms of academic influence in the field of orthopedics in China, based on H-index metrics. With over ten years of experience in biomedicine focusing on bone and cardiovascular diseases, as well as aptamer-based translational medicine and drug discovery, Prof. Zhang has published numerous high-impact articles in journals such as Nature Medicine, Nature Communications, Biomaterials, Arthritis & Rheumatism, and Theranostics. His work has been recognized by Nature Reviews Drug Discovery as a driving force for the future development and clinical evaluation of aptamers.

Biographies of Speakers



Professor CHEUNG Yiu Ming

Chair Professor, Hong Kong Baptist University

- Director, RGC Senior Research Fellow
- Dean of the Institute for Research and Continuing Education, HKBU
- Associate Director of Institute of Computational and Theoretical Studies, HKBU
- Stanford University: World's Top1% most cited Scientists in AI for 6 consecutive years

Prof. Cheung Yiu Ming is a Chair Professor (Artificial Intelligence) of the Department of Computer Science at Hong Kong Baptist University (HKBU). With a PhD in Computer Science from The Chinese University of Hong Kong, his research spans machine learning, visual computing, and their applications in data science, pattern recognition, and optimization.

Prof. Cheung is a Fellow of IEEE, AAAS, IAPR, IET, and BCS and has served as Editor-in-Chief of IEEE Transactions on Emerging Topics in Computational Intelligence. He has authored 300+ articles in premier venues such as TPAMI, TMM, and NeurIPS, with four ESI Highly Cited Papers. He holds three patents and has developed commercialized technologies like an eye-gaze tracking app for fatigue detection.

Prof. Cheung's accolades include gold medals at Geneva Invention Exhibitions, the APNNS Outstanding Achievement Award, and multiple best paper awards. In 2022, he founded IntelligenceX Limited, driving industry partnerships in AI-powered pharmaceutical R&D. His leadership secured TSSSU and HKSTP funding, enhancing the company's market presence and technological advancement.

Biographies of Speakers



Dr. LIU Edward Shiu Fai

Adjunct Investigator, The Institute for Innovation, Translation and Policy Research, Hong Kong Baptist University

- Fellow of the Royal College of Radiologists
- Fellow of Hong Kong College of Radiologists
- Fellow of the Hong Kong Academy of Medicine (Radiology)

Dr. Liu Edward Shiu Fai graduated from the University of Hong Kong with a M.B.,B.S. in 1993, and went on with his specialist training in clinical oncology. Meanwhile, he also graduated from HKU SPACE with B.C.M. and registered as a Chinese medicine practitioner. He then received further training in hyperthermic oncology and became a member of the European Society for Hyperthermic Oncology (ESHO).

In pursuit for further research in innovative cancer therapeutic approaches, Dr. Liu left the public service and set up his private oncology center. Dr. Liu has been actively involved in many research fields. He founded the startup “RadThera” in 2021, which at present is conducting the “CW7CD274” project for the development of a novel radiopharmaceutical for systemic radiotherapy.

In addition, Dr. Liu co-founded the Hong Kong-based company Health Hope Pharma (HHP), aiming to commercialize a very late-stage novel formulation for cancer treatment. Moreover, he is also the principal investigator, and responsible for the study center, of three international phase 3 clinical trials studying different classes of innovative breast cancer drugs. Last but not least, the GNS which is a late-stage project aiming at development of the best anti-emetic formulation, as an adjunct to every emetogenic cancer treatment he would use.

Biographies of Speakers



Dr. AIK Wei Shen

Assistant Professor, Hong Kong Baptist University

- Group Leader, Aik Lab

Dr. Wei Shen Aik is an Assistant Professor at the Department of Chemistry, HKBU. Dr. Aik completed his BA in Natural Sciences (Biochemistry) at the University of Cambridge. He then obtained a D.Phil. in chemical biology at the University of Oxford before being further trained in structural biology as a postdoctoral research scientist at Columbia University. His research in the 3D structures and biochemistry of protein-RNA complexes provides the fundamentals for the development of protein-based RNA therapeutics delivery agents.